Pasithea Therapeutics CORP Schedule 13G passive stakes

Opaleye Management Inc., Opaleye L.P., and James Silverman have jointly filed a Schedule 13G, reporting beneficial ownership of 2,050,000 shares of Pasithea Therapeutics Corp. common stock, representing 6.14% of the outstanding shares.

Coastlands Capital LP and affiliated entities have reported beneficial ownership of 11.48% of Pasithea Therapeutics Corp.'s common stock as of April 9, 2026.

Ameriprise Financial, Inc. and its subsidiary Columbia Management Investment Advisers, LLC have filed a Schedule 13G, reporting beneficial ownership of 5.4% of Pasithea Therapeutics Corp. common stock as of March 31, 2026.

Funicular Funds, LP, along with affiliated entities Cable Car Capital, LP and Jacob Ma-Weaver, has disclosed beneficial ownership of 1,839,512 shares, representing 7.4% of Pasithea Therapeutics Corp.'s common stock.

Opaleye Management Inc. and James Silverman have disclosed a significant passive investment in Pasithea Therapeutics Corp., acquiring nearly 10% of the company.

Coastlands Capital LP and its affiliates have disclosed a 9.99% beneficial ownership stake in Pasithea Therapeutics Corp., comprising common stock and pre-funded warrants.

CVI Investments and Heights Capital Management report a 3.8% passive stake in Pasithea Therapeutics Corp. via an amended Schedule 13G filing.

Squadron Master Fund LP and related entities disclose a 9.99% beneficial ownership stake in Pasithea Therapeutics Corp. common stock.

Ameriprise Financial and Columbia Management Investment Advisers have reported a combined beneficial ownership of 8.4% in Pasithea Therapeutics Corp. common stock.

Adage Capital Management, L.P. and its principals have reported a 9.99% beneficial ownership stake in Pasithea Therapeutics Corp. as of December 31, 2025.

Janus Henderson Group plc has reported a 9.99% beneficial ownership stake in Pasithea Therapeutics Corp., primarily through shared voting and dispositive power.

Squadron Capital Management LLC and its partners have reported a 9.99% beneficial ownership stake in Pasithea Therapeutics Corp. common stock.

Vivo Opportunity Fund Holdings and affiliates report a 9.99% beneficial ownership in Pasithea Therapeutics Corp., primarily through common stock and pre-funded warrants.

CVI Investments and Heights Capital Management report a 9.9% passive beneficial ownership stake in Pasithea Therapeutics Corp. common stock.

Armistice Capital, LLC and Steven Boyd have filed an amended Schedule 13G, reporting a continued beneficial ownership of 4.99% of Pasithea Therapeutics Corp.'s common stock as of March 31, 2025.

Mitchell P. Kopin, Daniel B. Asher, and Intracoastal Capital LLC have jointly disclosed a 4.99% beneficial ownership stake in Pasithea Therapeutics Corp. through a Schedule 13G filing, indicating a passive investment.

CVI Investments, Inc., managed by Heights Capital Management, Inc., has disclosed a 9.9% beneficial ownership stake in Pasithea Therapeutics Corp., totaling 627,319 shares.

Orca Capital AG has filed an amended Schedule 13G, reporting a beneficial ownership of 4.9% of Pasithea Therapeutics Corp.'s common stock.

Orca Capital AG, a German entity, has disclosed a 5.7% beneficial ownership stake in Pasithea Therapeutics Corp., holding 371,142 shares of common stock.

Armistice Capital, LLC and Steven Boyd have disclosed a beneficial ownership of 9.99% in Pasithea Therapeutics Corp.'s common stock as of December 31, 2024.